1+ hour, 52+ min ago  (347+ words) -- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- --March 20, 2026PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- Highlights from these 52-week data include: Setmelanotide…...

10+ hour, 53+ min ago  (179+ words) TOKYO, March 01, 2026 (GLOBE NEWSWIRE) -- OrganTech, Inc. announced that its research team has defined a minimal stem cell set required for functional hair follicle regeneration in vitro, establishing a defined cellular framework that may inform next-generation regenerative strategies for alopecia and…...

18+ hour, 20+ min ago  (358+ words) Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use Secondary endpoints also provided strong efficacy data in new analyses, including reduction in nasal congestion score (NCS) by…...

1+ day, 17+ hour ago  (236+ words) The agreement outlines a joint commitment to applying AI across various chronic care scenarios and upgrading full-lifecycle health management solutions. The two companies plan to build a more accessible, efficient, and precision-oriented healthcare service ecosystem, supporting the national shift in…...

1+ day, 18+ hour ago  (388+ words) Bezuclastinib mean TSS reduction deepens to "32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% o... Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting - Bezuclastinib mean TSS reduction deepens to…...

1+ day, 20+ hour ago  (415+ words) The FDA based its approval of YUVIWEL on their review of the clinical package for TransCon CNP submitted with the Company's New Drug Application, which included safety and efficacy data from three randomized, double-blind, placebo-controlled clinical trials and up to…...

2+ day, 5+ hour ago  (424+ words) " EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology's Genitourinary Cancers Symposium (ASCO-GU 2026) CR rates at three months were 83.9%, 81.2%, and 60.0% in patients with low (1-4), intermediate (5-9), and high (10-17) EORTC recurrence scores,…...

2+ day, 5+ hour ago  (746+ words) Rare Disease Day, observed annually on the last day of February, serves as an international campaign to raise awareness about the challenges faced by individuals and families living with rare diseases ... Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to…...

2+ day, 21+ hour ago  (651+ words) If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating…...

3+ day, 6+ hour ago  (652+ words) (PMV Pharma" or the Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that results from the ... New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of…...